# Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.

> **NCT04212026** · PHASE2 · TERMINATED · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 8 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04212026
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-28
- **Primary completion:** 2023-07-12
- **Final completion:** 2023-07-12
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** difficult recruitement
- **Last updated:** 2023-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04212026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04212026, "Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04212026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*